[PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?]
- PMID: 16133232
- DOI: 10.1007/s00120-005-0879-4
[PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?]
Abstract
PSA recurrence after primary curative therapy for localized prostate cancer is a common problem. Further curative treatment is only reasonable in the case of local recurrence. Therefore, minimizing the likelihood of metastatic disease is crucial. So far, imaging techniques cannot distinguish between local recurrence and distant metastasis. It is therefore reasonable to orientate on PSA kinetics and pathological criteria. Histologic confirmation of suspected local recurrence after radical prostatectomy before salvage therapy is not required. However, after initial radiation therapy histologic confirmation of suspected isolated local recurrence should be obtained. The optimal treatment for a PSA recurrence depends on the initial therapy and the life-expectancy of the patient.
Similar articles
-
Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma.Onkologie. 2005 Jun;28(6-7):361-6. doi: 10.1159/000085661. Epub 2005 Jun 2. Onkologie. 2005. PMID: 15933426 Review.
-
[PSA recurrence following radical prostatectomy and radiotherapy].Urologe A. 2006 Oct;45(10):1255-6, 1258-9. doi: 10.1007/s00120-006-1208-2. Urologe A. 2006. PMID: 17006700 Review. German.
-
[The significance of prostate-specific antigen in after-care of prostate carcinoma].Urologe A. 1998 Mar;37(2):170-1. doi: 10.1007/s001200050169. Urologe A. 1998. PMID: 9563130 German.
-
Rising PSA after a radical treatment.Eur Urol. 2001;40 Suppl 2:9-16. doi: 10.1159/000049879. Eur Urol. 2001. PMID: 11684859 Review.
-
Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies.Minerva Urol Nefrol. 2003 Dec;55(4):251-61. Minerva Urol Nefrol. 2003. PMID: 14765017 Review.
Cited by
-
Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation.Expert Rev Precis Med Drug Dev. 2023;8(1):33-42. doi: 10.1080/23808993.2023.2276927. Epub 2023 Nov 16. Expert Rev Precis Med Drug Dev. 2023. PMID: 37982134 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous